Browsing by Author "Giannakakis, T."
Now showing items 1-10 of 10
-
Article
Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients
Fountzilas, George; Polichronis, A.; Katsohis, C.; Gennatas, Constantinos; Toussis, D.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Vassilaros, S.; Semoglou, C.; Giannakakis, T.; Fahantidis, E.; Klouvas, G. D.; Tsavaris, N.; Konstantaras, C.; Makrantonakis, P.; Kolotas, C.; Zamboglou, N.; Tsiliakos, S.; Hainoglou, D.; Mylonakis, N.; Pavlidis, Nicholas (1996)362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 ...
-
Article
Diffuse large cell lymphomas: Identification of prognostic factors and validation of the international non-Hodgkin's Lymphoma Prognostic Index
Nikolaides, C.; Fountzilas, George; Zoumbos, N.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Pectasides, Dimitrios; Karabelis, A.; Giannakakis, T.; Symeonidis, A.; Papadopoulos, A.; Antoniou, F.; Pavlidis, Nicholas (1998)Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently ...
-
Article
High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study
Fountzilas, George; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Makrantonakis, P.; Tsavaris, N.; Kalogera-Fountzila, Anna; Giannakakis, T.; Beer, M.; Kosmidis, Paraskevas A. (1991)Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the ...
-
Article
High‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study
Fountzilas, George; Skarlos, Dimosthenis V.; Katsohis, C.; Pavlidis, Nicholas; Giannakakis, T.; Bafaloukos, Dimitrios; Fahantidis, E.; Klouvas, G. D.; Beer, M.; Kosmidis, Paraskevas A. (1995)The delivery of high‐dose epirubicin in patients with advanced breast cancer usually entails serious myelotoxicity and frequent treatment delays. Concurrent administration of G‐CSF probably allows the administration of ...
-
Article
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer
Fountzilas, George; Skarlos, Dimosthenis V.; Giannakakis, T.; Athanasiades, A.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Bamia, C.; Pavlidis, Nicholas; Kosmidis, Paraskevas A. (1994)50 women with advanced breast cancer were treated with an intensified regimen which consisted of high-dose epirubicin (110 mg/m2) every 2 weeks and filgrastim (5 μg/kg) subcutaneously for 13 days, starting 24 h after ...
-
Article
Phase II Study of 5-Fluorouracil and Interferon-Gamma in Patients with Metastatic Colorectal Cancer
Pavlidis, Nicholas; Nikolaides, C.; Athanasiades, A.; Beriatou, K.; Skarlos, Dimosthenis V.; Giannakakis, T.; Kosmidis, Paraskevas A.; Karvounis, N.; Fountzilas, George (1996)Preclinical data have shown a synergism between 5-fluorouracil and interferon-γ against human colon carcinoma cell lines. We conducted a phase II trial of this combination in 34 patients with metastatic colorectal cancer. ...
-
Article
A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group Study
Janinis, J.; Giannakakis, T.; Athanasiades, A.; Fountzilas, George; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Nikolaides, C.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (2000)Aims and background: The purpose of this multicenter randomized, open- label, parallel-group study was to assess whether the addition of low-dose dexamethasone to ondansetron results in improved control of chemotherapy- ...
-
Article
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study
Fountzilas, George; Athanasiades, A.; Giannakakis, T.; Briassoulis, E. Ch; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Onienaoum, A.; Kalofonos, H. P.; Pectasides, Dimitrios; Andreopoulou, E.; Bamia, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)Purpose: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. Patients and methods: From January 1991 until April ...
-
Article
Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma
Bafaloukos, Dimitrios; Pavlidis, Nicholas; Fountzilas, George; Skarlos, Dimosthenis V.; Klouvas, G. D.; Makrantonakis, P.; Giannakakis, T.; Tsavaris, N.; Kosmidis, Paraskevas A. (1996)Thirty-four patients with advanced malignant melanoma were treated with recombinant alpha-interferon (IFN) and chemotherapy consisting of carboplatin, vinblastine, and bleomycin (CVB). CVB was given for four cycles and IFN ...
-
Article
Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin
Nikolaides, C.; Giannakakis, T.; Skarlos, Dimosthenis V.; Athanasiades, A.; Fountzilas, George; Damigos, D.; Pavlidis, Nicholas (1998)Tropisetron is a novel selective antagonist of the type-3 serotonin (5- HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of >100 mg/m2 has a high emetogenic ...